In patients receiving T2D medication, the mean change was -3.2% as compared to -5.9% of those who were being treated for obesity
En el caso de Wegovy, cuya dosis por inyeccin es mayor 2,4 mg a la dosis por inyeccin mayor de Ozempic 2 mg, la FDA aprob su uso para el tratamiento de adultos con obesidad o sobrepeso y alguna condicin como presin alta o colesterol alto
\ Bones can become less dense as we lose weight for any reasoneven moderate decreases in weight can cause bone loss
Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon] Instruct patients beginning treatment with VYVANSE about the risk of peripheral vasculopathy, including Raynaud's phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change from pale, to blue, to red